Universal DX
Develops blood-based early cancer detection tests for clinical and healthcare partners
Highlights
- New on EvolcAdded 2026-11-14
About Universal DX
Universal DX is a bioinformatics and multi-omics company developing blood tests to detect cancer at an early stage. Its Signal-C liquid biopsy test targets colorectal cancer and advanced adenomas, using multi-omics, computational biology and machine learning.
The company is building a multi-cancer detection platform and works with clinical institutions and gastrointestinal clinical teams. It has a strategic collaboration with Quest Diagnostics to support access to Signal-C in the United States after FDA approval.
Universal DX says its work began in 2012 and describes an international research team and clinical network across the United States and Europe. Open roles include research and development, reagent quality control, legal counsel and biomedical equipment management.
Product: Blood-based liquid biopsy tests and a multi-cancer detection platform.
Jobs at Universal DX
More biotech & pharma companies
Valo Health
AI-enabled drug discovery and development for pharmaceutical and biotech partnersNew on EvolcVaxart
Develops oral pill vaccines for infectious diseases for public health and healthcare marketsNew on EvolcVaxcyte
Clinical-stage vaccine developer making pneumococcal, Group A Strep and Shigella vaccines for children and at-risk adultsRemote-friendlyVerastem
Develops and commercializes targeted cancer therapies for patients with RAS/MAPK pathway-driven cancersNew on EvolcViatris
Global pharmaceutical company supplying generic, branded and innovative medicines to patients and healthcare markets worldwideVilya
AI-driven drug design company creating novel macrocycle therapeutics for diseases with limited treatment optionsNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Tag ManagerMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Integration code on pageinline script loader
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Website resourcedeclared script/iframe or software asset
- Response headerserver
Content management
- WebflowHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- AWSHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Recruiting
- GreenhouseMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Page markupsoftware structure signature
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.